Phenelzine: An old drug that may hold clues to the development of new neuroprotective agents

Klinik Psikofarmakoloji Bulteni

Volumn 20, Issue 2, 2010, Pages 179-186

  MacKenzie, Erin M ^a   Song, Mee Sook ^a   Dursun, Serdar M ^a   Tomlinson, Sara ^a   Todd, Kathryn G ^a   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Glutamate; Neuroprotection; Phenelzine; Primary amine oxidase (semicarbazide sensitive amine oxidase); Reactive aldehydes; aminobutyric acid (GABA)

Indexed keywords

3 AMINOPROPANAL; 4 AMINOBUTYRIC ACID; ACROLEIN; ALDEHYDE DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMYLOID BETA PROTEIN; BETA PHENYLETHYLIDENEHYDRAZINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; FORMALDEHYDE; GLUTAMIC ACID; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; PROTEIN P75; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID BRAIN LEVEL; APOPTOSIS; ASTROCYTE; BRAIN ISCHEMIA; CELL LOSS; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; EXCITOTOXICITY; GABAERGIC TRANSMISSION; LIPID PEROXIDATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

EID: 77957164538     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.1080/10177833.2010.11790656     Document Type: Review

References (89)

1. McGrath PJ, Stewart JW, Harrison W, Wager S, Quitkin FM. Phenelzine treatment of melancholia. J Clin Psychiatry 1986; 47:420-422.
2. Paykel ES, Rowan PR, Parker RR, Bhat AV. Response to phenelzine and amitriptyline in subtypes of outpatient depression. Arch Gen Psychiatry 1982; 39 :1041-1049. (Pubitemid 12020987)
3. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wager SG, Ocepek-Welikson K, Nunes E, Rabkin JG, Klein DF. Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Arch Gen Psychiatry 1990; 47 :935-941.
4. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Wager SG, Nunes E, Rabkin JG, Tricamo E, Markowitz J, Klein DF. Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 1989; 46:787-793.
5. Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987; 48:55-59. (Pubitemid 17049430)
6. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37:51-59.
7. Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D, Hollander E, Papp L, Goetz D. Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988; 49:252-257.
8. Wood PL, Khan MA, Kulow SR, Mahmood SA, Moskal JR. Neurotoxicity of reactive aldehydes: the concept of "aldehyde load" as demonstrated by neuroprotection with hydroxylamines. Brain Res 2006; 1095:190-199.
9. Baker GB, LeGatt DF, Coutts RT, Dewhurst WG. Rat brain concentrations of 5-hydroxytryptamine following acute and chronic administration of MAO-inhibiting antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8:653-656. (Pubitemid 15193219)
10. McKenna KF, Baker GB, Coutts RT. N2-Acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn Schmiedeberg's Arch Pharmacol 1991; 343:478-482.
11. Griebel G, Curet O, Perrault G, Sanger DJ. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and antipanic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. Neuropharmacology 1998; 37:927-935.
12. McKim RH, Calverly DG, Dewhurst WG, Baker GB. Regional concentrations of cerebral amines: effects of tranylcypromine and phenelzine. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7:783-786.
13. Philips SR, Boulton AA. The effect of monoamine oxidase inhibitors on some arylalkylamines in rat striatum. J Neurochem 1979; 33:159-167. (Pubitemid 9233922)
14. McManus DJ, Baker GB, Martin IL, Greenshaw AJ, McKenna KF. Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-transaminase activity in rat brain. Biochem Pharmacol 1992; 43:2486-2489.
15. Popov N, Matthies H. Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain. J Neurochem 1969; 16:899-907.
16. Paslawski TM, Sloley BD, Baker GB. Effects of the MAO inhibitor phenelzine on glutamine and GABA concentrations in rat brain. Prog Brain Res 1995; 106:181-186.
17. Parent MB, Habib MK, Baker GB. Time-dependent changes in brain monoamine oxidase activity and in brain levels of monoamines and amino acids following acute administration of the antidepressant/ antipanic drug phenelzine. Biochem Pharmacol 2000; 59:1253-1263.
18. Perry TL, Hansen S. Sustained drug-induced elevation of brain GABA in the rat. J Neurochem 1973; 21:1167-1175.
19. Baker GB, Wong JT, Yeung JM, Coutts RT. Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA). J Affect Disord 1991; 21:207-211.
20. Parent MB, Habib MK, Baker GB. Task-dependent effects of the antidepressant/antipanic drug phenelzine on memory. Psychopharmacology (Berl) 1999; 142:280-288.
21. Todd KG, Baker GB. GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord 1995; 35:125-129.
22. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB. Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol 2001; 21:325-339.
23. Yu PH, Boulton AA. A comparison of the effect of brofaromine, phenelzine and tranylcypromine on the activities of some enzymes involved in the metabolism of different neurotransmitters. Res Commun Chem Path Pharmacol 1992; 16:141-153.
24. Dyck LE, Dewar KM. Inhibition of aromatic L-amino acid decarboxylase and tyrosine aminotransferase by the monoamine oxidase inhibitor phenelzine. J Neurochem 1986; 46:1899-1903.
25. Holt A, Berry MD, Boulton AA. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology 2004; 25:251-266.
26. Paslawski T. The antipanic drug phenelzine and its effects on GABA and related amino acids. Edmonton, AB, Canada: University of Alberta; 1998.
27. Yang J, Shen J. In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine. Neuroscience 2005; 135:927-937.
28. Michael-Titus AT, Bains S, Jeetle J, Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience 2000; 100:681-684.
29. Duffy S, Nguyen PV, Baker GB. Phenylethylidenehydrazine, a novel GABA-transaminase inhibitor, reduces epileptiform activity in rat hippocampal slices. Neuroscience 2004; 126:423-432. (Pubitemid 38780818)
30. Clineschmidt BV, Horita A. The monoamine oxidase catalyzed degradation of phenelzine-1-14C, an irreversible inhibitor of monoamine oxidase - I: Studies in vitro. Biochem Pharmacol 1969 18: 1011-1020.
31. Parent MB, Master S, Kashlub S, Baker GB. Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum. Biochem Pharmacol 2002; 63:57-64.
32. Paslawski T, Knaus E, Iqbal N, Coutts RT, Baker GB. β- Phenylethylidenehydrazine, a novel inhibitor of GABA transaminase. Drug Develop Res 2001; 54:35-39.
33. Tanay VA, Todd KG, Baker GB. Phenylethylidenehydrazine, a novel GABA-T inhibitor, rescues neurons from cerebral ischemia. Proceedings of the 23rd Congress of the Collegium Internationale Neuropsychopharmacologicum. Montreal, Canada; 2002.
34. Kanthan R, Shuaib A, Griebel R, Miyashita H. Intracerebral human microdialysis. In vivo study of an acute focal ischemic model of the human brain. Stroke 1995; 26:870-873.
35. Juurlink BHJ, Sweeney MI. Mechanisms that result in damage during and following cerebral ischemia. Neurosci Biobehav Rev 1997; 21:121-128.
36. Iqbal S, Baziany A, Gordon S, Wright S, Hussain M, Miyashita H, Shuaib A, Hasan Rajput A. Neuroprotective effect of tiagabine in transient forebrain global ischemia: an in vivo microdialysis, behavioral, and histological study. Brain Res 2002; 946:162-170. (Pubitemid 34876328)
37. Yang Y, Li Q, Miyashita H, Yang T, Shuaib A. Different dynamic patterns of extracellular glutamate release in rat hippocampus after permanent or 30-min transient cerebral ischemia and histological correlation. Neuropathology 2001; 21:181-187.
38. Mainprize T, Shuaib A, Ijaz S, Kanthan R, Miyashita H, Kalra J. GABA concentrations in the striatum following repetitive cerebral ischemia. Neurochemical Res 1995; 20:957-961.
39. Shuaib A, Ijaz S, Miyashita H, Mainprize T, Kanthan R. Progressive decrease in extracellular GABA concentrations in the post-ischemic period in the striatum: a microdialysis study. Brain Res 1994; 666:99-103.
40. Baldwin HA, Jones JA, Cross AJ, Green AR. Histological, biochemical and behavioural evidence for the neuroprotective actions of chlormethiazole following prolonged carotid artery occlusion. Neurodegen 1993; 2:139-146.
41. Zeng X, Zhang Y, Zhang S, Zheng X. A microdialysis study of effects of gastrodin on neurochemical changes in the ischemic /reperfused rat cerebral hippocampus. Biol Pharm Bull 2007; 30:801-804. (Pubitemid 46570994)
42. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology 2000; 39:1483-1494.
43. Schwartz-Bloom RD, Sah R. gamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia. J Neurochem 2001; 77:353-371.
44. Green AR, Cross AJ, Snape MF, De Souza RJ. The immediate consequences of middle cerebral artery occlusion on GABA synthesis in mouse cortex and cerebellum. Neurosci Lett 1992; 138:141-144.
45. Kang TC, Park SK, Bahn JH, Chang JS, Koh WS, Jo SM, Cho SW, Choi SY, Won MH. Elevation of the gamma-aminobutyric acid transaminase expression in the gerbil CA1 area after ischemia-reperfusion damage. Neurosci Lett 2000; 294:33-36.
46. Shuaib A, Ijaz S, Hasan S, Kalra J. Gamma-vinylGABA prevents hippocampal and substantia nigra reticulata damage in repetitive transient forebrain ischemia. Brain research 1992; 590:13-17.
47. Shuaib A, Murabit MA, Kanthan R, Howlett W, Wishart T. The neuroprotective effects of gamma-vinyl GABA in transient global ischemia: a morphological study with early and delayed evaluations. Neurosci Lett 1996; 204:1-4.
48. Scott HL, Tannenberg AE, Dodd PR. Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex. J Neurochem 1995; 64:2193-2202.
49. Liang Z, Valla J, Sefidvash-Hockley S, Rogers J, Li R. Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer's disease patients. J Neurochem 2002; 80:807-814.
50. Cowburn R, Hardy J, Roberts P, Briggs R. Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease. Neurosci Lett 1988; 86:109-113. (Pubitemid 18064401)
51. Lanctot KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry 2004; 49:439-453.
52. Seiler N. Oxidation of polyamines and brain injury. Neurochem Res 2000; 25:471-490.
53. Matyus P, Dajka-Halasz B, Foldi A, Haider N, Barlocco D, Magyar K. Semicarbazide-sensitive amine oxidase: current status and perspectives. Curr Med Chem 2004; 11:1285-1298.
54. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11:81-128. (Pubitemid 121003917)
55. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, Suzuki D, Miyata T, Noguchi N, Niki E, Osawa T. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci U S A 1998; 95:4882-4887.
56. Tomitori H, Usui T, Sakei N, Ueda S, Kase H, Nishimura K, Kashiwagi K, Igarashi K. Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. Stroke 2005; 36:2603-2613.
57. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 2001; 22:187-194.
58. Picklo MJ, Montine TJ. Acrolein inhibits respiration in isolated brain mitochondria. Biochim Biophys Acta 2001; 1535:145-152.
59. Ivanova S, Botchkina GI, Al-Abed Y, Meistrell M, 3rd, Batliwalla F, Dubinsky JM, Iadecola C, Wang H, Gregersen PK, Eaton JW, Tracey KJ. Cerebral ischemia enhances polyamine oxidation: identification of enzymatically formed 3-aminopropanal as an endogenous mediator of neuronal and glial cell death. J Exp Med 1998; 188:327-340.
60. Li W, Yuan XM, Ivanova S, Tracey KJ, Eaton JW, Brunk UT. 3- Aminopropanal, formed during cerebral ischaemia, is a potent lysosomotropic neurotoxin. Biochem J 2003; 371:429-436. (Pubitemid 36547626)
61. Gubisne-Haberle D, Hill W, Kazachkov M, Richardson JS, Yu PH. Protein cross-linkage induced by formaldehyde derived from semicarbazide-sensitive amine oxidase-mediated deamination of methylamine. J Pharmacol Exp Ther 2004; 310:1125-1132.
62. White JS, Rees KR. The mechanism of action of 4-hydroxynonenal in cell injury. Chem Biol Interact 1984; 52:233-241.
63. Horton ND, Mamiya BM, Kehrer JP. Relationships between cell density, glutathione and proliferation of A549 human lung adenocarcinoma cells treated with acrolein. Toxicol 1997; 122:111-122.
64. Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D. Antioxidant therapy in acute central nervous system injury: current state. Pharmacol Rev 2002; 54:271-284. (Pubitemid 34575717)
65. Kazachkov M, Chen K, Babiy S, Yu PH. Evidence for in vivo scavenging by aminoguanidine of formaldehyde produced via semicarbazide-sensitive amine oxidase-mediated deamination. J Pharmacol Exp Ther 2007; 322:1201-1207.
66. Burcham PC, Kaminskas LM, Fontaine FR, Petersen DR, Pyke SM. Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology 2002; 181-182:229-236.
67. Galvani S, Coatrieux C, Elbaz M, Grazide MH, Thiers JC, Parini A, Uchida K, Kamar N, Rostaing L, Baltas M, Salvayre R, Negre- Salvayre A. Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic Biol Med 2008; 45:1457-1467.
68. MacKenzie EM, Grant SL, Baker GB, Wood PL. Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res 2008; 33:430-436.
69. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998; 19:33-36.
70. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997; 68:2092-2097. (Pubitemid 27176147)
71. Calingasan NY, Uchida K, Gibson GE. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem 1999; 72:751-756.
72. Pocernich CB, Butterfield DA. Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotoxicol Res 2003; 5:515-520.
73. Chen K, Maley J, Yu PH. Potential inplications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J Neurochem 2006; 99:1413-1424. (Pubitemid 44730095)
74. Nie CL, Wei Y, Chen X, Liu YY, Dui W, Liu Y, Davies MC, Tendler SJB, He RG. Formaldehyde at low concentration induces protein tau into globular amyloid-like aggregates in vitro and in vivo. PLoS ONE 2007; 2:e629.
75. Ferrer I, Lizcano JM, Hernandez M, Unzeta M. Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett 2002; 321:21-24. (Pubitemid 34185489)
76. Yu PH. Involvement of cerebrovascular semicarbazide-sensitive amine oxidase in the pathogenesis of Alzheimer's disease and vascular dementia. Med Hypotheses 2001; 57:175-179.
77. Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 1980; 49:1-20. (Pubitemid 10030548)
78. Jossan SS, Gillberg PG, Gottfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study. Neuroscience 1991; 45:1-12.
79. Cao X, Wei Z, Gabriel GG, Li X, Mousseau DD. Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology. BMC Neurosci 2007; 8:73. (Pubitemid 350031913)
80. Cantoni O, Fumo M, Cattabeni F. Role of metal ions in oxidant cell injury. Biol Trace Elem Res 1989; 21:277-281. (Pubitemid 19256369)
81. Lizcano JM, Fernandez de Arriba A, Tipton KF, Unzeta M. Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol 1996; 52:187-195. (Pubitemid 26233747)
82. Lewinsohn R. Amine oxidase in human blood vessels and non-vascular smooth muscle. J Pharm Pharmacol 1981; 33:569-575. (Pubitemid 11028290)
83. Zuo D, Yu PH. Semicarbazide-sensitive amine oxidase and monoamine oxidase in rat brain microvessels, meninges, retina and eye sclera. Brain Res Bull 1993; 33:307-311. (Pubitemid 124010048)
84. del Mar Hernandez M, Esteban M, Szabo P, Boada M, Unzeta M. Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging. Neurosci Lett 2005; 384:183-187. (Pubitemid 40826641)
85. Segal RA. Selectivity in neurotrophin signaling: theme and variations. Ann Rev Neurosci 2003; 26:299-330.
86. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 2008; 1211:37-43.
87. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59:1116-1127. (Pubitemid 43912554)
88. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34:13-25.
89. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nature Rev Neurosci 2006; 7:295-309.